3 Biotechs Rake In $272M In IPO Rush
Three biotechs — an immuno-oncology treatment developer, a cancer antibody developer and a fungal treatment developer — splashed onto the Nasdaq on Wednesday, together drawing $272 million in capital as initial...To view the full article, register now.
Already a subscriber? Click here to view full article